HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I trial of elactocin.

Abstract
Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed.
AuthorsE S Newlands, G J Rustin, M H Brampton
JournalBritish journal of cancer (Br J Cancer) Vol. 74 Issue 4 Pg. 648-9 (Aug 1996) ISSN: 0007-0920 [Print] England
PMID8761384 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Controlled Clinical Trial, Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Fatty Acids, Unsaturated
  • leptomycin B
Topics
  • Anorexia
  • Antibiotics, Antineoplastic (administration & dosage, adverse effects, therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Fatty Acids, Unsaturated (administration & dosage, adverse effects, therapeutic use)
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: